WO2006042745A3 - Chemisch modifizierte iapp - peptidanaloga - Google Patents

Chemisch modifizierte iapp - peptidanaloga Download PDF

Info

Publication number
WO2006042745A3
WO2006042745A3 PCT/EP2005/011211 EP2005011211W WO2006042745A3 WO 2006042745 A3 WO2006042745 A3 WO 2006042745A3 EP 2005011211 W EP2005011211 W EP 2005011211W WO 2006042745 A3 WO2006042745 A3 WO 2006042745A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemically modified
modified peptide
peptide analogs
methods
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/011211
Other languages
English (en)
French (fr)
Other versions
WO2006042745A2 (de
Inventor
Juergen Bernhagen
Afroditi Kapurniotu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheinisch Westlische Technische Hochschuke RWTH
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Rheinisch Westlische Technische Hochschuke RWTH
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rheinisch Westlische Technische Hochschuke RWTH, Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Rheinisch Westlische Technische Hochschuke RWTH
Priority to EP05806441A priority Critical patent/EP1805215A2/de
Priority to US11/666,043 priority patent/US20100221240A1/en
Priority to CA002584263A priority patent/CA2584263A1/en
Priority to JP2007537192A priority patent/JP2008517885A/ja
Publication of WO2006042745A2 publication Critical patent/WO2006042745A2/de
Publication of WO2006042745A3 publication Critical patent/WO2006042745A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)

Abstract

Die vorliegende Erfindung betrifft verbesserte Mittel und Verfahren zur Behandlung von Diabetes und Alzheimer-Krankheit unter Ver­wendung von IAPP-Peptidderivaten.
PCT/EP2005/011211 2004-10-20 2005-10-18 Chemisch modifizierte iapp - peptidanaloga Ceased WO2006042745A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05806441A EP1805215A2 (de) 2004-10-20 2005-10-18 Chemisch modifizierte iapp-peptidanaloga
US11/666,043 US20100221240A1 (en) 2004-10-20 2005-10-18 Chemically Modified Peptide Analogs
CA002584263A CA2584263A1 (en) 2004-10-20 2005-10-18 Chemically modified peptide analogs
JP2007537192A JP2008517885A (ja) 2004-10-20 2005-10-18 化学修飾ペプチド類似体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004051014A DE102004051014A1 (de) 2004-10-20 2004-10-20 Chemisch modifizierte Peptidanaloga
DE102004051014.8 2004-10-20

Publications (2)

Publication Number Publication Date
WO2006042745A2 WO2006042745A2 (de) 2006-04-27
WO2006042745A3 true WO2006042745A3 (de) 2006-11-30

Family

ID=36039892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011211 Ceased WO2006042745A2 (de) 2004-10-20 2005-10-18 Chemisch modifizierte iapp - peptidanaloga

Country Status (7)

Country Link
US (1) US20100221240A1 (de)
EP (1) EP1805215A2 (de)
JP (1) JP2008517885A (de)
KR (1) KR20080000554A (de)
CA (1) CA2584263A1 (de)
DE (1) DE102004051014A1 (de)
WO (1) WO2006042745A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868688A1 (en) 2012-04-03 2013-10-10 Trustees Of Boston University Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
MX389762B (es) * 2014-03-12 2025-03-20 Neurimmune Holding Ag Novedosos compuestos capaces de antagonizar el daño a las celulas-beta y la tolerancia deteriorada a la glucosa inducidos por el polipeptido amiloide de los islotes (iapp).
CA2947587C (en) 2014-05-02 2022-10-18 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
JP6734258B2 (ja) * 2015-03-04 2020-08-05 栄研化学株式会社 オキシトシンの高感度測定法
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
WO2019036673A1 (en) * 2017-08-18 2019-02-21 The Medical College Of Wisconsin, Inc. THERAPY BASED ON SRCP1 FOR DISEASES ASSOCIATED WITH PROTEIN AGGREGATION
JP7505713B2 (ja) * 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
US20240067693A1 (en) * 2020-12-16 2024-02-29 Medimmune Limited Polypeptides and uses thereof
TWI880227B (zh) 2022-05-30 2025-04-11 丹麥商西蘭製藥公司 澱粉素類似物之液體調配物
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy
TW202504913A (zh) 2023-06-21 2025-02-01 丹麥商西蘭製藥公司 減重
CN121358489A (zh) 2023-06-21 2026-01-16 西兰制药公司 具有改善特性的类似物
AU2024306538A1 (en) 2023-06-30 2025-12-04 Zealand Pharma A/S Combination therapy
WO2025150507A1 (ja) * 2024-01-12 2025-07-17 学校法人東邦大学 インスリン・アミロイド化重合蛋白質、抗体、抗体産生ｂ細胞および医療用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263802A1 (de) * 1986-10-08 1988-04-13 Per Westermark Materialzusammensetzung, welche ein Polypeptid aus Pankreas-Insel-Amyloid und/oder Antikörpern gegen dieses Polypeptid enthält, und Anwendung dieser Zusammensetzung
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US20020119926A1 (en) * 2000-09-19 2002-08-29 Paul Fraser Inhibitors of IAPP fibril formation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280014A (en) * 1988-01-11 1994-01-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263802A1 (de) * 1986-10-08 1988-04-13 Per Westermark Materialzusammensetzung, welche ein Polypeptid aus Pankreas-Insel-Amyloid und/oder Antikörpern gegen dieses Polypeptid enthält, und Anwendung dieser Zusammensetzung
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US20020119926A1 (en) * 2000-09-19 2002-08-29 Paul Fraser Inhibitors of IAPP fibril formation and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANATSUKA A ET AL: "ISLET AMYLOID POLYPEPTIDE AND ITS N-TERMINAL AND C-TERMINAL FLANKING PEPTIDES' IMMUNOREACTIVITY IN ISLET AMYLOID OF DIABETIC PATIENTS", DIABETES RESEARCH AND CLINICAL PRACTICE, AMSTERDAM, NL, vol. 26, no. 2, 1994, pages 101 - 107, XP001056212, ISSN: 0168-8227 *

Also Published As

Publication number Publication date
DE102004051014A1 (de) 2006-04-27
WO2006042745A2 (de) 2006-04-27
US20100221240A1 (en) 2010-09-02
JP2008517885A (ja) 2008-05-29
EP1805215A2 (de) 2007-07-11
CA2584263A1 (en) 2006-04-27
KR20080000554A (ko) 2008-01-02

Similar Documents

Publication Publication Date Title
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
HUS1600047I1 (hu) Eljárások hipoglikémiás szerek beadására
IL182716A (en) Method for purifying recombinant fsh
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
AP2350A (en) Method for the preparation of sevoflurane.
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
ZA200702523B (en) Process for the purification of 1,4-butanediol
IL186748A0 (en) 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility
WO2007106792A3 (en) Methods for treating sarcopenia with a growth hormone secretagogue
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
WO2005075412A3 (en) Norbornane based cycloaliphatic compounds containing nitrile groups
WO2006110724A3 (en) Method of treating schizophrenia prodrome
PT1934252E (pt) Processo para a preparação de conjugados de insulina
EP1884514A4 (de) Verfahren zur optischen trennung von 2-amino-6 propylamino-4,5,6,7-tetrahydrobenzothiazol und zwischenprodukte
EP1753446A4 (de) Alpha-1-säure-glykoprotein zur behandlung von diabetes
TW200702331A (en) Process for preparing alkylanilides
PL374461A1 (pl) Sposób otrzymywania pochodnych 13,14-dihydro-PGF
EP1750698A4 (de) Für die behandlung von diabetes geeignete 5-anilino-4-heteroarylpyrazol-derivate
ZA200702070B (en) Process for preparing substituted 8-azablcyclo[3.2.1] octan-3-ols
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
PL1627881T3 (pl) Sposób otrzymywania topiramatu
WO2007007151A3 (en) Use of anti-mad-cam antibody for the treatment of emphysema
EP1883628A4 (de) Verbessertes verfahren zur herstellung von 3,5-diethyl-1,2-dihydro-1-phenyl-2-propylpyridin
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
UA87709C2 (ru) Способ очищения фолликулостимулирующего гормона

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005806441

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2584263

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007537192

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11666043

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020077011199

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005806441

Country of ref document: EP